Co-expression of Cytokeratin and Vimentin in Colorectal Cancer Highlights a Subset of Tumor Buds and an Atypical Cancer-associated Stroma
Overview
Authors
Affiliations
Tumor buds in colorectal cancer are hypothesized to undergo a (partial) epithelial-mesenchymal transition (EMT). If so, cytokeratin (CK) and vimentin (VIM) co-expression is expected. CK+/VIM+ can also be found in some stromal cells; however, their origin remains unclear. Here, we determine the frequency of CK+/VIM+ tumor cells and characterize the CK+/VIM+ stroma in colorectal cancer. Three cell populations (CK+, VIM+, CK+/VIM+) were sorted using DepArray and fluorescence-activated cell sorting (FACS). Tumor areas were selected to include tumor center, stroma and tumor budding. Fluorescence microscopy was used to visualize co-expressing cells on whole slides. A next-generation tissue microarray (ngTMA) of matched Pan-CK-positive and -negative stroma was constructed and stained for E-cadherin, VIM, Snail1, Twist1, Zeb1 and Zeb2, COL11A1, SPARC, CD90, α-SMA, FAP and WT1. CK+/VIM+ co-expressing tumor cells were detected using all three methods. With DepArray, only tumor budding areas contained CK+/VIM+ cells. The proportion of CK+/VIM+ tumor cells was low (1.5%-22%). CK+ stroma was associated with aggressive tumor features like distant metastasis (P = .0003), lymphatic invasion (P = .0009) and tumor budding (P = .0084). CK+/VIM+ stroma was characterized by positive WT1 (P < .001), ZEB2 (P < .001), TWIST1 (P = .009), and FAP (P = .003). Our data suggest that CK+/VIM+ tumor cells exist, albeit in low numbers and could represent a subgroup of tumor buds in partial EMT. CK+/VIM+ stroma may be of mesothelial origin and shows features of mesenchymal cells and cancer-associated fibroblasts. These results, together with the association with metastasis point to cells in mesothelial-mesenchymal transition (MMT). This atypical stroma may be a potential target for therapy.
Tumor budding - a potential biomarker in low grade salivary gland carcinomas?.
Burkhardt V, Kayser G, Villing T, Becker C Front Oncol. 2024; 14:1410264.
PMID: 38983934 PMC: 11231199. DOI: 10.3389/fonc.2024.1410264.
Precisional detection of lymph node metastasis using tFCM in colorectal cancer.
Yang D, Tang J, Zhen Y, Yuan J, Hu P, Li X Open Life Sci. 2023; 18(1):20220780.
PMID: 38152574 PMC: 10751999. DOI: 10.1515/biol-2022-0780.
Okuyama K, Suzuki K, Yanamoto S Cancers (Basel). 2023; 15(4).
PMID: 36831453 PMC: 9953904. DOI: 10.3390/cancers15041111.
Shen R, Li P, Zhang B, Feng L, Cheng S J Transl Med. 2022; 20(1):462.
PMID: 36209225 PMC: 9548187. DOI: 10.1186/s12967-022-03661-8.
WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease.
Lee W, Chiu C, Chu T, Chien Y Front Cell Dev Biol. 2022; 10:876723.
PMID: 35465313 PMC: 9019781. DOI: 10.3389/fcell.2022.876723.